ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha

Aronrag Meeyai1,2, Naiyana Praditsitthikorn1,3, Surachai Kotirum1, Wantanee Kulpeng1,Weerasak Putthasri4, Ben S. Cooper5,6*, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Nonthaburi, Thailand, 2 Department of Epidemiology, Faculty of Public Health, Mahidol University

Roongnapa Khampang1,2, Sawitri Assanangkornchai2, Linda B Cottler3. 1Epidemiology Unit, Faculty of Medicine, Prince of Songkhla University, Hatyai, Thailand, 2Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health, Nonthaburi, Thailand, 3College

Phanthipha Wongwai a, Pritaporn Kingkaew b, Somkiat Asawaphureekorn a, Tharatip Kolatat c aDepartment of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40000, Thailand bHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi 11000, Thailand cDepartment of Pa

Thanthima Suwanthawornkul1, Thunyarat Anothaisintawee2*, Abhasnee Sobhonslidsuk3, Ammarin Thakkinstian4, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand, 2 Department of Family Medicine, Faculty of Medicine, Ramathibodi

CATHERINE PITTa,* ANNA VASSALLa, YOT TEERAWATTANANONb, ULLA K. GRIFFITHSa, LORNA GUINNESSa, AMIAN WALKERc, NICOLA FOSTERd and KARA HANSONa a Department of Global Health & Development, London School of Hygiene & Tropical Medicine, London, UK b Health Intervention and Technology Assess

Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

K. Chittawatanarat a, *, K. Tosanguan b, U. Chaikledkaew b, c, S. Tejavanija d, Y. Teerawattananon b a Division of Trauma and Critical Care, Department of Surgery, Faculty of Medicine, Maharaj Nakorn Chiang Mai Hospital, Intawarorod Road, Sripume, Chiang Mai University, Chiang Mai 50200, Thailand

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac